Why do COX-2 inhibitors increase risk of cardiovascular events?

Lancet. 2002 Apr 20;359(9315):1410. doi: 10.1016/S0140-6736(02)08393-9.
No abstract available

Publication types

  • News

MeSH terms

  • Animals
  • Anti-Inflammatory Agents, Non-Steroidal / adverse effects*
  • Cyclooxygenase 2
  • Cyclooxygenase 2 Inhibitors
  • Cyclooxygenase Inhibitors / adverse effects*
  • Cyclooxygenase Inhibitors / pharmacology
  • Humans
  • Isoenzymes / antagonists & inhibitors*
  • Lactones / adverse effects*
  • Membrane Proteins
  • Mice
  • Myocardial Infarction / chemically induced*
  • Naproxen / adverse effects
  • Prostaglandin-Endoperoxide Synthases
  • Sulfones
  • Thromboxane A2 / metabolism*

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Cyclooxygenase 2 Inhibitors
  • Cyclooxygenase Inhibitors
  • Isoenzymes
  • Lactones
  • Membrane Proteins
  • Sulfones
  • rofecoxib
  • Thromboxane A2
  • Naproxen
  • Cyclooxygenase 2
  • PTGS2 protein, human
  • Prostaglandin-Endoperoxide Synthases